Intra-Cellular Therapies Inc

General ticker "ITCI" information:

  • Sector: Health Care
  • Industry: Pharmaceuticals
  • Capitalization: $8.7B (TTM average)

Intra-Cellular Therapies Inc follows the US Stock Market performance with the rate: 31.2%.

Estimated limits based on current volatility of 0.1%: low 131.73$, high 131.93$

Factors to consider:

  • Current price 39.4% above estimated high

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [50.76$, 94.63$]
  • 2025-12-31 to 2026-12-31 estimated range: [37.17$, 73.42$]

Financial Metrics affecting the ITCI estimates:

  • Negative: Non-GAAP EPS, $ of -0.73 <= 0.04
  • Negative: negative Operating income
  • Negative: negative Net income
  • Negative: Operating cash flow per share per price, % of -0.83 <= 1.81
  • Negative: Industry operating cash flow per share per price (median), % of -7.67 <= 2.91

Similar symbols

Short-term ITCI quotes

Long-term ITCI plot with estimates

Financial data

YTD 2022-12-31 2023-12-31 2024-12-31
Operating Revenue $250.31MM $464.37MM $680.85MM
Operating Expenses $513.94MM $623.75MM $797.57MM
Operating Income $-263.63MM $-159.38MM $-116.72MM
Non-Operating Income $7.38MM $20.34MM $42.52MM
R&D Expense $134.72MM $180.14MM $236.12MM
Income(Loss) $-256.25MM $-139.04MM $-74.20MM
Taxes $0.01MM $0.64MM $0.47MM
Profit(Loss)* $-256.26MM $-139.67MM $-74.68MM
Stockholders Equity $656.07MM $591.42MM $1,148.46MM
Inventory $23.92MM $11.65MM $26.28MM
Assets $754.78MM $728.29MM $1,366.91MM
Operating Cash Flow $-270.19MM $-124.20MM $-73.18MM
Capital expenditure $0.78MM $0.27MM $0.32MM
Investing Cash Flow $-128.37MM $105.54MM $-335.15MM
Financing Cash Flow $455.16MM $17.81MM $567.51MM
Earnings Per Share** $-2.72 $-1.46 $-0.72

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.